18F-fluoromisonidazole ([18F]FMISO) has been exploited in positron emission tomography (PET) as an imaging radiotracer for tumor hypoxia. The accumulation of [18F]FMISO must depend on both hypoxia and perfusion. In this study, we investigated [18F]FMISO activity in the AT1 tumor rat model and found that [18F]FMISO produced conflicting results in the poorly perfused hypoxic tumors. The preliminary results indicate that BOLD and TOLD MRI can provide complimentary information for interpretation of the [18F]FMISO results.
This abstract and the presentation materials are available to members only; a login is required.